Hero image with Pittsburgh background https://pittplusme.org/study/2233

This study is not currently recruiting. Please check back at a later time.

STUDY BASICS

Have you been diagnosed with (by liver biopsy), or are you at high risk of developing (have type 2 diabetes, are obese, and/or have high cholesterol), nonalcoholic steatohepatitis (NASH)? You may be able to participate in a study to evaluate an investigational drug for its ability to treat NASH. This study involves 21 visits and up to 9 phone calls over 5 years. Compensation is provided.


IRB: 20203645
- The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Age Range
AGE:   18 and up
Duration
DURATION:  About 5 years
VISITS:  21 visits & up to 9 phone calls
Location
LOCATION:  Kaufmann Building - Oakland
Compensation
COMPENSATION:  Up to $600
Location
PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit https://pittplusme.org/study/2233 and click on "I'm Interested" or call 1-866-438-8230.

LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Mordechai Rabinovitz

Mordechai Rabinovitz, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh. A graduate of Tel-Aviv University in Israel, Dr. Rabinovitz’s research interests include assessment and treatment of chronic viral hepatitis as well as developing new therapies for non-alcoholic fatty liver disease.